Drugs / Measles, Mumps and Rubella Combined Vaccine, Live
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05161845 | Dec 2021 → Apr 2022 | immune system disorder | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, Mumps and Rubella Combined Vaccine, Live | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05161845 ↗ |
| Known as | MMR | “A Phase IV Randomized, Blinded Clinical Trial to Assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) Lot-to-lot Consistency in Healthy Chinese Children at the Age of...” NCT05161845 ↗ |
| Modality | Vaccine | “Measles, Mumps and Rubella Combined Vaccine, Live” NCT05161845 ↗ |